Pacific Biosciences of California (PACB) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this maker of genetic analysis technology have returned -49.7% over the past month versus the Zacks S&P 500 composite's -4.2% change. The Zacks Medical - Instruments industry, to which Pacific Biosciences belongs, has lost 4.3% over this period. Now the key question is: Where could the st ...

Pacific Biosciences of California (PACB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently announced preliminary revenues for first-quarter 2024. Despite the soft preliminary results, the company’s shares gained 7.1% in the pre-market trading session.The company is scheduled to release first-quarter results on May 9.Per the preliminary report, first-quarter 2024 total revenues are estimated to be $38.8 million, down 0.3% year over year. The Zacks Consensus Estimate of $50 million lies above the preliminary figure ...

文章核心观点 - 公司第一季度收入低于预期,主要原因包括客户推迟仪器购买、耗材出货疲软等 [6][7][8][9] - 公司预计2024年全年收入将在170-200百万美元之间,低于此前预期 [11] - 公司计划通过成本削减措施,将2024年全年非GAAP经营费用降低5000-7500万美元 [10] - 公司表示长期增长前景仍然看好,正在采取措施提高商业执行力、提升毛利率等 [10][11] 根据目录分类总结 财务数据 - 第一季度初步收入为3880万美元,与上年同期基本持平 [2] - 其中仪器收入1900万美元,耗材收入1600万美元,服务及其他收入380万美元 [2][3] - 第一季度共出货28台Revio测序系统,截至3月31日累计安装201台 [4] - 截至3月31日,公司现金及投资余额约为5.62亿美元 [5] 业务表现 - 公司认为客户推迟仪器购买、耗材出货疲软等因素导致第一季度业绩低于预期 [6][7][8][9] - 公司表示将采取措施提高商业执行力,推动Revio和Onso平台的市场渗透 [10] - 公司预计第二季度收入将好于第一季度,下半年随着耗材收入恢复增长而有所改善 [11] 未来展望 - 公司预计2024年全年收入将在170-200百万美元之间,低于此前预期 [11] - 公司计划通过成本削减措施,将2024年全年非GAAP经营费用降低5000-7500万美元 [10] - 公司表示长期增长前景仍然看好,正在采取措施提高毛利率等 [10][11] - 公司表示可能无法在2026年实现至少5亿美元的收入目标,正在重新评估实现该目标的时间 [12]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its slew of strategic deals over the past few months. The optimism, led by a solid fourth-quarter 2023 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist.Over the past year, this currently Zacks Rank #3 (Hold) stock has lost 70.5% against the 10.1% growth of the industry. The S&P 500 rose 24.9% in the same time fra ...

MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity In ...

Pacific Biosciences of California (PACB) , popularly known as PacBio,recently announced the PureTarget repeat expansion panel, a new approach that makes it possible to thoroughly examine 20 genes linked to severe neurological conditions, including difficult-to-sequence genes with tandem repeat expansions, is now possible.In addition to cutting down on the amount of time required to find disease-causing variations and the methylation signatures that go along with them, the new long-read process can eliminate ...

HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological DiseaseMENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________ Form 10-K ________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t ...

财务表现 - PacBio在2023年第四季度的调整后每股亏损为27美分，比去年同期的35美分的亏损更窄[1] - PacBio在第四季度的营收为5840万美元，同比增长113.3%，超过了Zacks Consensus Estimate[4] - PacBio全年调整后每股亏损为1.11美元，比2022年同期的1.38美元的亏损更窄[3] - PacBio在美洲地区的营收为3390万美元，同比增长182%[6] - PacBio的产品营收为5400万美元，比去年同期增长137.1%[8] 产品和技术 - PacBio在2023年第四季度共发货了44台Revio测序系统，截至2023年12月31日，公司的安装基数为173台[9] - PacBio在2023年第四季度发布了SMRT Link 13.0软件和Kinnex RNA kits，以及在2024年1月发布了PanDNA DNA提取套件[20] 财务展望 - PacBio在2023年第四季度的调整后毛利润增长了59.9%，但调整后毛利率下降了826个基点至24.7%[11] - PacBio在2023年底的现金、现金等价物和投资为6.314亿美元，较2022年底的7.723亿美元有所下降[15] - PacBio预计2024年的营收将在2.3亿至2.5亿美元之间，增长率为15-25%[17] 股票评级 - PacBio目前持有Zacks Rank 3 (Hold)[23]